1970 related articles for article (PubMed ID: 16230722)
21. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
[TBL] [Abstract][Full Text] [Related]
22. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
[TBL] [Abstract][Full Text] [Related]
23. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
24. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Arnolds S; Dellweg S; Clair J; Dain MP; Nauck MA; Rave K; Kapitza C
Diabetes Care; 2010 Jul; 33(7):1509-15. PubMed ID: 20357372
[TBL] [Abstract][Full Text] [Related]
25. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
26. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
27. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
[TBL] [Abstract][Full Text] [Related]
30. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
31. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
McCall AL; Cox DJ; Brodows R; Crean J; Johns D; Kovatchev B
Diabetes Technol Ther; 2009 Jun; 11(6):339-44. PubMed ID: 19459761
[TBL] [Abstract][Full Text] [Related]
32. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
33. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
35. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
36. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.
Bunck MC; Cornér A; Eliasson B; Heine RJ; Shaginian RM; Wu Y; Yan P; Smith U; Yki-Järvinen H; Diamant M; Taskinen MR
Atherosclerosis; 2010 Sep; 212(1):223-9. PubMed ID: 20494360
[TBL] [Abstract][Full Text] [Related]
37. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
38. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Zinman B; Philis-Tsimikas A; Cariou B; Handelsman Y; Rodbard HW; Johansen T; Endahl L; Mathieu C;
Diabetes Care; 2012 Dec; 35(12):2464-71. PubMed ID: 23043166
[TBL] [Abstract][Full Text] [Related]
39. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
40. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
